Parvovirus B19 Myocarditis: Looking Beyond the Heart

Izquierdo-Blasco, Jaume; Allende, M.T.; Grau, Maria Gemma Codina; Gran, Ferrán; Martinez-Saez, Elena; Balcells, Joan

doi:10.1177/1093526619865641

Cited by 4 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Contrary to other viruses, B19V infects coronary endothelium rather than cardiac muscle cells. The course of B19V myocarditis is different from myocarditis caused by other viruses, as the damaged endothelial cells cause myocardial ischemia and cardiac dysfunction [22][23][24].…”

Section: Rare Manifestations Of Parvovirus B19 Infectionmentioning

confidence: 99%

Parvovirus B19 infection during pregnancy

Pietruszka

Sliwinska

Sikora

2022

Current Issues in Pharmacy and Medical Sciences

View full text Add to dashboard Cite

Parvovirus B19 (B19V) is a widespread pathogen causing infection that occurs mostly in children. Even though infection of B19V is mainly asymptomatic, it can bring about a few conditions that may require medical intervention, including erythema infectiosum (fifth disease), slapped cheek syndrome, papular-purpuric gloves and socks syndrome (PPGSS), as well as other disorders related to the hematological system. Despite the fact that the most common route of transmission is through the respiratory system, B19V can be also transmitted transplacentally from mother to foetus. Vertical transmission may lead to myocarditis, thrombocytopenia, neural manifestations, and foetal hydrops, which may be life-threatening conditions to both mother and foetus. Detection of B19V infection is based mostly on molecular and serological screening and it is performed after suspected exposure to pathogen or exhibition of symptoms. Currently, there is no specific medication against B19V infection, therefore, treatment is based on the elimination of symptoms. New therapies are, however, under development.

show abstract

Section: Rare Manifestations Of Parvovirus B19 Infectionmentioning

confidence: 99%

Parvovirus B19 infection during pregnancy

Pietruszka

Sliwinska

Sikora

2022

Current Issues in Pharmacy and Medical Sciences

View full text Add to dashboard Cite

show abstract

“…This is a literature review of 32 reported pediatric cases of B19V-associated myocarditis [ 29 - 53 ]. We found that immunosuppressive drugs and immunoglobulin administration may lead to good outcomes in pediatric patients (p-value 0.006 and 0.004, respectively) but this could be related to a limited number of cases.…”

Section: Reviewmentioning

confidence: 99%

Parvovirus B19-Associated Myocarditis: A Literature Review of Pediatric Cases

Keramari¹,

Poutoglidis²,

Chatzis³

et al. 2022

Cureus

View full text Add to dashboard Cite

Parvovirus B19 (B19V) infection may lead to myocarditis, a life-threatening condition in pediatric patients. In this review, we aim to present published pediatric cases of B19V-associated myocarditis in order to understand the deep complex connections and draw useful conclusions. We performed a comprehensive search of MEDLINE, Science Direct, and Google Scholar electronic databases. A total of 32 cases were included in our study. The most common presenting symptom was tachycardia in 22/32 patients (68.7%), followed by tachypnoea (21/32, 65.6%), fever, and rash (12/32, 37.5% for both of them). Cardiac arrest, loss of consciousness, and systemic infection were associated with the worst prognosis, with statistically significant differences (p-value 0.001, 0.02, 0.001. respectively). A percentage as high as 90.4% of patients with left ventricular (LV) dysfunction and reduced ejection fraction (EF) were discharged. Twelve patients required ventilatory support, five required extracorporeal membrane oxygenation (ECMO), and three underwent heart surgery. Treatment with immunosuppressive agents and immunoglobulin was found to be beneficial for patients (p-value 0.006 and 0.004, respectively). In conclusion, B19V myocarditis has high mortality rates in children. There is no specific antiviral treatment for B19V infection and therapeutic strategies for myocarditis aim to delay the worsening of heart failure and to preserve the LV function. Inotropic drugs, diuresis, ventilatory support, Intravenous immunoglobulin (IVIG), and immunosuppressive therapy seem to help the recovery of the myocardium in children with LV dilation, dysfunction, and reduced EF. Children with cardiac arrest, arrhythmias, and loss of consciousness have the worst prognosis.

show abstract

“…Pri otrocih opisujejo tudi primere miokarditisa. Parvovirus B19 se rad veže na celice srËne mišice in povzroËi imunsko posredovane okvare miokarda s hipoksiËno-ishe-miËnimi okvarami (10). V primerjavi s šesto otroško boleznijo, ki je znaËilna za dojenËke in majhne otroke, se peta otroška bolezen pojavlja pretežno pri šolskih otrocih.…”

Section: Prikaz Primeraunclassified